The Company and Summary of Significant Accounting Policies - Basic and Diluted Net Income (Loss) per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Net income attributable to Jazz Pharmaceuticals plc	$ 111,282	$ 88,114	$ 185,403	$ 158,814
Denominator:
Weighted-average ordinary shares used in per share calculations - basic (in shares)	60,499	61,190	60,821	60,998
Dilutive effect of employee equity incentive and purchase plans (in shares)	1,334	1,900	1,333	2,030
Weighted-average ordinary shares - diluted (in shares)	61,833	63,090	62,154	63,028
Net income attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic net income (in dollars per share)	$ 1.84	$ 1.44	$ 3.05	$ 2.60
Diluted net income (in dollars per share)	$ 1.80	$ 1.40	$ 2.98	$ 2.52